
The industry has seen it coming for some time, but in its most recent fiscal report, Lundbeck establishes: The Danish pharmaceutical company will be targeting niches in neurology and psychiatry going forward.
The firm is ready to shelve its large, broad indications – to a certain extent. As indicated in the annual report, the firm plans to focus on niches in neurology and psychiatry, or on rare neurological diseases, Lundbeck's Executive Vice President and Head of Research & Development Johan Luthman tells MedWatch after a year of reorganizations in his department.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app